Biogen Idec jumps after BG-12 data

Biogen Idec Inc. (NASDAQ:BIIB) gained $13.13 (15%) to $99.70 on Thursday after reporting additional data from the Phase III DEFINE trial of oral multiple sclerosis (MS) candidate BG-12. Twice-daily BG-12

Read the full 303 word article

How to gain access

Continue reading with a
two-week free trial.